President and CEO
Bill Gruber joined Solace Therapeutics in August 2011 as President and CEO. Prior to this role, he co-founded Interlace Medical in August 2006 and served as their President and CEO until Interlace was acquired by Hologic in January 2011. Bill has extensive experience in organizational development and in product development for rapid growth businesses. Prior to Interlace, Bill spent five years at Cortek Inc., a spinal products company. As Cortek’s V.P. of Sales and Marketing, he built sales from $612K to over $10M. During his last two years, he was the V.P. of New Business Development and Marketing. In this role, he was instrumental in creating Soteira, a Cortek subsidiary, focused on devices for treating vertebral compression fractures. Prior to Cortek, Bill spent 10 years at Boston Scientific Corporation. Before leaving Boston Scientific Corporation, he held the position of Director of the $172M Global Atherosclerotic Therapy business. Prior to entering the medical device sector, Bill spent five years in sales and marketing roles at Procter and Gamble.
Vice President of R&D and Operations
Albert joined Solace Therapeutics in January 2014 as Vice President of Research and Development. Prior to this, he served as VP of R&D for Interlace Medical since inception through January 2011 and continued on as VP of R&D for Hologic post acquisition through 2013. Albert has over 20 years experience and a proven track record in technology and product development of minimally invasive medical devices from concept to commercialization. Prior to Interlace, he was director of R&D for Neurotechnologies at Codman, a J&J company, where he managed a $3M+ budget and successfully launched three new products in electrosurgery, neuro monitoring and biologics markets. Prior to Codman, he spent 11 years in Corporate Technology Group at Boston Scientific Corporation as R&D/Program Manager managing new product development projects with budgets ranging from $2M to $20M. During his time at Boston Scientific Corporation, he co-founded two internal startups which led to the formation of two new divisions in Neurointervention and Endovascular businesses. He has 15 issued patents on proprietary technology platforms for multiple medical devices with annual revenues over $100M. Prior to Boston Scientific Corporation, he was an R&D engineer for Kendall Company.
Nicole Joined Solace Therapeutics in March 2012 as Vice President of Marketing. Prior to this, she served as Director of Marketing for Interlace Medical from March 2009 through January 2011. She continued on with Hologic post acquisition through October 2011 to help lead launch efforts of the MyoSure hysteroscopic fibroid removal franchise throughout Hologic’s sales organization both domestically and Internationally. Nicole has extensive experience within women’s health. She brings a successful track record for introducing new treatments and technologies within the medical device arena and has fostered numerous relationships within the industry and with key opinion leaders in Urology and Gynecology both domestically and internationally. She has held senior marketing roles with companies such as Candela Corporation, the Women’s Healthcare Division of Boston Scientific Corporation, Laboratory Corporation of America, Davol (a division of CR Bard), GE Medical, (formerly Datex-Ohmeda) and Bayer Diagnostics (formerly Ciba-Corning Diagnostics).
Vice President of Regulatory and Clinical Affairs
Joshua Freeman joined Solace Therapeutics in August 2012. Prior to his role as Vice President of Clinical Affairs, he spent 15 years at Health Policy Associates, Inc. a boutique consulting firm serving the medical device and biotechnology industry. At Health Policy Associates, Josh gained extensive experience in clinical development, working with dozens of small medical device companies to help them meet goals and milestones to obtain and keep necessary investment. During his last two years, he was the VP of the company helping several clients gain critical regulatory approvals that served as major inflection points for their continued growth.